- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04694157
Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease Patients
Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease Patients - An Observational Long-term Study
CAD is a challenging affliction which has a high annual morbidity rate in China and the world. Severe CAD may lead to compromised cardiac function, decreased exertional capacity and poor quality of life (QOL). The most common treatment for CAD is medication, percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). However, some patients had long-term of history with complex severe artery lesions, they are not candidate for redo interventional therapy. Cardiac shock wave therapy (CSWT) is an exploring therapy used globally for CAD patients, which is known for its safety, non-invasiveness and effectiveness.The previous RCT from the investigators' team has already finished, and results are in submission processing.
This is a prospective, single arm, observational study design. CAD patients will be enrolled consecutively. The entire treatment period will last 3 months with 9 sessions. Outcomes are assessed as efficacy outcomes and safety outcomes. Efficacy outcomes include symptom (CCS score, NYHA classification, nitroglycerin dosage, SAQ questionnaire), exertional capacity (6MWT), quality of life (SF-36 questionnaire) and imaging evaluation (myocardial perfusion imaging and echocardiography). Safety outcome include the change of serum TNT, CKMB, BNP and adverse event (AE) occurrence. The participants will be followed up at 13th week, 6th months and 12th months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
CAD is a challenging affliction which has a high annual morbidity rate in China and the world. Severe CAD may lead to compromised cardiac function, decreased exertional capacity and poor quality of life (QOL). The most common treatment for CAD is medication, percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). However, some patients had long-term of history with complex severe artery lesions, they are not candidate for redo interventional therapy. Cardiac shock wave therapy (CSWT) is an exploring therapy used globally for CAD patients, which is known for its safety, non-invasiveness and effectiveness. In the previous clinical studies, CSWT can alleviated angina symptom, improved myocardial ischemia and increased exertional capacity. Many single arm studies proved its efficacy and safety. Our RCT has already finished, and results are in submission processing.
This is a prospective, single arm, observational study design. CAD patients will be enrolled consecutively. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, follow by a 3-week non-treatment interval. Outcomes are assessed as efficacy outcomes and safety outcomes. Efficacy outcomes include symptom (CCS score, NYHA classification, nitroglycerin dosage, SAQ questionnaire), exertional capacity (6MWT), quality of life (SF-36 questionnaire) and imaging evaluation (myocardial perfusion imaging and echocardiography). Safety outcome include the change of serum TNT, CKMB, BNP and adverse event (AE) occurrence. Symptom, 6MWT and questionnaires will be evaluated at baseline and 13th week, 6th months, 12th months of CSWT. Imaging outcomes will be evaluated at baseline and 13th week, 12th months of CSWT. The level of TNT, CKMB and BNP will be tested before and 1st week after initiation of CSWT.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Lingling Yu, MD
- Phone Number: +8601085138105
- Email: bjyyec@126.com
Study Contact Backup
- Name: Wei Liu
- Phone Number: +8601085138105
- Email: bjyyec@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Beijing Hospital
-
Contact:
- Lingling Yu
- Phone Number: +8601085138105
- Email: bjyyec@126.com
-
Contact:
- Liu
- Phone Number: +8601085138105
- Email: bjyyec@126.com
-
Principal Investigator:
- Qing He, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Multiple or diffused coronary artery stenosis via coronary angiography, and not the candidates for PCI or CABG;
- Myocardial ischemia documented by stressed MPI and echocardiography;
- Refractory angina that has not been alleviated after at least three months of optimal medication treatment (OMT);
- Left ventricular ejection fraction (LVEF) ≥ 30%.
Exclusion Criteria:
- Acute myocardial infarction within one month;
- PCI or CABG within one month;
- Heart transplant patient;
- Patients with prosthetic valves;
- Cases of atrial or ventricular thrombosis;
- Uncontrolled heart failure with LVEF <30%;
- Severe arrhythmia; (viii) patients with pacemakers;
- Cases of infective endocarditis;
- Chronic obstructive pulmonary disease patients;
- Pregnant or nursing women;
- Patients with silicone breast implants;
- Chest tumor patients;
- Patients already participating in other clinical trials.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Treatment group
The treatment group will receive cardiac shock wave therapy.
The CSWT entire treatment will period last 3 months with 9 sessions.
CSWT will administered in the first week, followed by a 3-week non-treatment interval.
|
Two target segments of left ventricle will be chosen for all participants.
In each target segment, 9 sties will be administered with 200 shots at each site.
Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating.
The entire treatment period will last 3 months with 9 sessions.
CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summed Rest Score
Time Frame: Change from Baseline Summed Rest Score at 12 months.
|
Summed Rest Score of 17 segments of left ventricle under myocardial perfusion imaging.
Each segment will be scored from 0 to 4. The minimum score is 0 while the maximum score is 68.
Higher score means worse ischemia.
|
Change from Baseline Summed Rest Score at 12 months.
|
Summed Stress Score
Time Frame: Change from Baseline Summed Stress Score at 12 months.
|
Summed Stress Score of 17 segments of left ventricle under myocardial perfusion imaging.
Each segment will be scored from 0 to 4. The minimum score is 0 while the maximum score is 51.
Higher score means worse ischemia.
|
Change from Baseline Summed Stress Score at 12 months.
|
Summed Reverse Score
Time Frame: Change from Baseline Summed Reverse Score at 12 months.
|
Summed Reverse Score of 17 segments of left ventricle under myocardial perfusion imaging.
Each segment will be scored from 0 to 4. The minimum score is 0 while the maximum score is 51.
Higher score means worse ischemia.
|
Change from Baseline Summed Reverse Score at 12 months.
|
Regional Rest Score
Time Frame: Change from Baseline Regional Rest Score at 12 months.
|
Rest Score of target treatment segments of left ventricle under myocardial perfusion imaging.
Each segment will be scored from 0 to 4. The minimum score is 0 while the maximum score is 8. Higher score means worse ischemia.
|
Change from Baseline Regional Rest Score at 12 months.
|
Regional Stress Score
Time Frame: Change from Baseline Regional Stress Score at 12 months.
|
Stress Score of target treatment segments of left ventricle under myocardial perfusion imaging will be calculate.
Each segment will be scored from 0 to 4. The minimum score is 0 while the maximum score is 8. Higher score means worse ischemia.
|
Change from Baseline Regional Stress Score at 12 months.
|
Regional Reverse Score
Time Frame: Change from Baseline Regional Reverse Score at 12 months.
|
Reverse Score of target treatment segments of left ventricle under myocardial perfusion imaging will be calculate.
Each segment will be scored from 0 to 4. The minimum score is 0 while the maximum score is 8. Higher score means worse ischemia.
|
Change from Baseline Regional Reverse Score at 12 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CCS score
Time Frame: Change from Baseline CCS score at 12 months.
|
Canadian Cardiovascular Society score.
The score is from 1 to 4 score.
Higher score means worse ischemia.
|
Change from Baseline CCS score at 12 months.
|
NYHA classification
Time Frame: Change from Baseline NYHA classification at 12 months.
|
Now York Heart Association classification.
The score is from 1 to 4. Higher score means worse heart function.
|
Change from Baseline NYHA classification at 12 months.
|
Seattle Angina Questionnaire
Time Frame: Change from Baseline NYHA classification at 12 months.
|
Seattle Angina Questionnaire has five domain: physical limitation, angina stability, angina frequency, treatment satisfaction and quality of life.
Each domain are 0-100 scale.
|
Change from Baseline NYHA classification at 12 months.
|
QOL: SF-36 Questionnaire
Time Frame: Change from Baseline SF-36 score at 12 months.
|
SF-36 Questionnaire include vitality, physical functioning, body pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health.
Each items are 0-100 scale.
|
Change from Baseline SF-36 score at 12 months.
|
Six minutes walk test
Time Frame: Change from Baseline 6MWT at 12 months.
|
Six minutes walk test proceed according to ATS guideline.
The total distance will be recored.
|
Change from Baseline 6MWT at 12 months.
|
Left ventricular ejection fraction
Time Frame: Change from Baseline status at 12 months
|
Left ventricular ejection fraction on echocardiography
|
Change from Baseline status at 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac enzyme
Time Frame: Change from Baseline status at 13th week after treatment.
|
Serum Troponin T, CKMB
|
Change from Baseline status at 13th week after treatment.
|
Brain Natrium Peptide
Time Frame: Change from Baseline status at 13th week after treatment.
|
Serum brain Natrium Peptide
|
Change from Baseline status at 13th week after treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Qing He, MD, Beijing Hospital
Publications and helpful links
General Publications
- Zhang Y, Shen T, Liu B, Dai D, Cai J, Zhao C, Du L, Jia N, He Q. Cardiac Shock Wave Therapy Attenuates Cardiomyocyte Apoptosis after Acute Myocardial Infarction in Rats. Cell Physiol Biochem. 2018;49(5):1734-1746. doi: 10.1159/000493616. Epub 2018 Sep 24.
- Qiu Q, Shen T, Wang Q, Yu X, Jia N, He Q. Cardiac shock wave therapy protects cardiomyocytes from hypoxia-induced injury by modulating miR-210. Mol Med Rep. 2020 Feb;21(2):631-640. doi: 10.3892/mmr.2019.10892. Epub 2019 Dec 18.
- Liu B, Zhang Y, Jia N, Lan M, Du L, Zhao D, He Q. Study of the Safety of Extracorporeal Cardiac Shock Wave Therapy: Observation of the Ultrastructures in Myocardial Cells by Transmission Electron Microscopy. J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):79-88. doi: 10.1177/1074248417725877. Epub 2017 Sep 1.
- Du L, Shen T, Liu B, Zhang Y, Zhao C, Jia N, Wang Q, He Q. Shock Wave Therapy Promotes Cardiomyocyte Autophagy and Survival during Hypoxia. Cell Physiol Biochem. 2017;42(2):673-684. doi: 10.1159/000477885. Epub 2017 Jun 15.
- Yu W, Shen T, Liu B, Wang S, Li J, Dai D, Cai J, He Q. Cardiac shock wave therapy attenuates H9c2 myoblast apoptosis by activating the AKT signal pathway. Cell Physiol Biochem. 2014;33(5):1293-303. doi: 10.1159/000358697. Epub 2014 Apr 28.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 121-2016004-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
Clinical Trials on cardiac shock wave therapy
-
Shanghai 10th People's HospitalUnknown
-
Ya-Wei XuScience and Technology Commission of Shanghai MunicipalityRecruitingMyocardial Infarction With Non-obstructive Coronary Arteries | Cardiac Shock Wave TherapyChina
-
Beijing HospitalCompleted
-
Kunming Medical UniversityCompletedCoronary Artery DiseaseChina
-
Rodrigo Marcel Valentim da SilvaUniversidade Federal do Rio Grande do NorteCompletedPain | Muscle Tonus
-
Northern Orthopaedic Division, DenmarkCompletedChronic Inflammatory Disorder
-
The First Affiliated Hospital of Kunming Medical...Not yet recruitingST Elevation Myocardial Infarction | Myocardial Reperfusion Injury | Prognosis | Treatment Outcome
-
Yuzuncu Yıl UniversityCompleted
-
Isfahan University of Medical SciencesUnknownPlantar FasciitisIran, Islamic Republic of
-
Yonsei UniversityUnknownPost-Stroke Elbow SpasticityKorea, Republic of